Business
Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia
In 4 completed studies and the ongoing OL study, 65 participants received at least 1 dose of nomlabofusp, including 39 in the OL study, with 14 on treatment for at least 6 months and 8 for over 1 year in the OL studyIncreases in skin FXN levels with short- and long-term daily nomlabofusp; 10/10 participants with data at 6 months achieved skin FXN levels over 50% of median levels in healthy volunteers (which is similar to levels in asymptomatic carriers)Consistent directional improvement across 4
About this update from Larimar Therapeutics, Inc.
[{"type":"image","alt":"Larimar Therapeutics","displaySize":"","headline":null,"caption":"Larimar Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":107,"url":"https://media.zenfs.com/en/globenewswire.com/59a0cb6afa06818e6bf352c70da11d95"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1uUrf9fLQ_8GcyV6eEAsEw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/59a0cb6afa06818e6bf352c70da11d95","width":300,"height":107}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"In 4 completed studies and the ongoing OL study, 65 participants received at least 1 dose of nomlabofusp, including 39 in the OL study, with 14 on treatment for at least 6 months and 8 for over 1 year in the OL study","length":216,"tagName":"p"}]},{"val":[{"type":"text","content":"Increases in skin FXN levels with short- and long-term daily nomlabofusp; 10/10 participants with data at 6 months achieved skin FXN levels over 50% of median levels in healthy volunteers (which is similar to levels in asymptomatic carriers)","length":241,"tagName":"p"}]},{"val":[{"type":"text","content":"Consistent directional improvement across 4 key clinical outcomes (mFARS, FARS-ADL, 9-HPT, MFIS) observed after 1 year of nomlabofusp treatment could suggest potential for clinical benefit relative to a worsening in a FACOMS natural history study reference population","length":267,"tagName":"p"}]},{"val":[{"type":"text","content":"Anaphylaxis has been reported in 7 participants in the OL study, with most events occurring on the initial day of administration and all occurring within the first 6 weeks of dosing; excluding these events, long term dosing of nomlabofusp was generally well tolerated","length":267,"tagName":"p"}]},{"val":[{"type":"text","content":"Following the 2 most recent cases of anaphylaxis, Larimar consulted its experts and decided to modify its starting dose regimen; Larimar provided the FDA a full update on the clinical development program including the safety, FXN, and clinical data in this press release and FDA agreed with our approach","length":303,"tagName":"p"}]},{"val":[{"type":"text","content":"BLA submission seeking accelerated approval targeted in Q2 2026","length":63,"tagName":"p"}]},{"val":[{"type":"text","content":"Company management to host webcast and conference call...